Clinical Trials Logo

Solid Tumors (Phase 1) clinical trials

View clinical trials related to Solid Tumors (Phase 1).

Filter by:
  • None
  • Page 1

NCT ID: NCT02765165 Terminated - Clinical trials for Solid Tumors (Phase 1)

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Start date: April 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, Phase 1/2, dose-escalation and dose expansion study of a CXCR4 inhibitor, USL311, alone and in combination with lomustine in subjects with advanced solid tumors (Phase 1) and subjects with relapsed/recurrent GBM (Phase 2). The study is designed to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of USL311 alone and in combination with lomustine.